The juggernaut keeping CSL’s valuation pumping despite Ozempic threat
A casual visitor to the ASX from another universe watching CSL’s valuation shrink in 2023 would not know that CSL had been a mainstay of Australian share portfolios – yielding the best, most consistent returns of any large company – since its listing in 1994.
The blood products giant had temporarily succumbed to the “Ozempic effect” – the idea that the new generation of wonder weight-loss drugs would dramatically improve the health of people struggling with obesity and make them far less susceptible to chronic diseases such as diabetes and heart disease.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles